Ozempic maker Novo Nordisk wants the FDA to stop pharmacies from making off-brand versions of popular weight loss meds
qz.com › novo-nordisk-fda-ozempic-wegovy-1851679536
This story seems to be about:
This story seems to be about:
Ozempic maker Novo Nordisk (NVO) is asking the U.S. Food and Drug Administration (FDA) to prohibit compounding pharmacies from making off-brand versions of semaglutide, the active ingredient in its blockbuster weight loss and diabetes medications.